Combination of Encorafenib and Binimetinib Followed by Ipilimumab and Nivolumab Versus Ipilimumab and Nivolumab in Patients with Advanced Melanoma with BRAFV600E or BRAFV600K Mutations (EBIN): an International, Open-Label, Randomised, Controlled, Phase 2 Study.

Caroline Robert, Michal Kicinski,Caroline Dutriaux,Émilie Routier, Anne-Sophie Govaerts, Emanuel Bührer,Eve-Marie Neidhardt,Xavier Durando, Barouyr Baroudjian,Philippe Saiag, Caroline Gaudy-Marqueste,Paolo A Ascierto, Ana Arance,Michelangelo Russillo,Jean-Luc Perrot,Laurent Mortier,Francois Aubin,Stéphane Dalle,Florent Grange, Eva Muñoz-Couselo, Sorilla Mary-Prey, Mona Amini-Adle,Sandrine Mansard,Céleste Lebbe, Elisa Funck-Brentano, Sandrine Monestier, M, Felix Oppong, Leen Wijnen, Bastian Schilling, Mario MandalÁ, Paul Lorigan, Alexander C J van Akkooi

The Lancet Oncology（2025）

引用 0|浏览1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要